bluebird bio, Inc. (BLUE) Shares Bought by Legal & General Group Plc

Legal & General Group Plc increased its stake in bluebird bio, Inc. (NASDAQ:BLUE) by 32.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 20,076 shares of the biotechnology company’s stock after purchasing an additional 4,912 shares during the period. Legal & General Group Plc’s holdings in bluebird bio were worth $2,762,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Tocqueville Asset Management L.P. boosted its stake in shares of bluebird bio by 78.0% during the 3rd quarter. Tocqueville Asset Management L.P. now owns 55,690 shares of the biotechnology company’s stock worth $7,649,000 after buying an additional 24,400 shares during the last quarter. Quantitative Investment Management LLC boosted its stake in shares of bluebird bio by 1,193.8% during the 2nd quarter. Quantitative Investment Management LLC now owns 104,800 shares of the biotechnology company’s stock worth $11,009,000 after buying an additional 96,700 shares during the last quarter. State of Wisconsin Investment Board acquired a new position in shares of bluebird bio during the 2nd quarter worth about $3,257,000. Janus Henderson Group PLC acquired a new position in shares of bluebird bio during the 2nd quarter worth about $5,252,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of bluebird bio during the 2nd quarter worth about $1,061,000.

bluebird bio, Inc. (NASDAQ:BLUE) opened at $181.10 on Wednesday. bluebird bio, Inc. has a fifty-two week low of $60.95 and a fifty-two week high of $222.03. The company has a market cap of $8,803.03, a P/E ratio of -25.80 and a beta of 2.08.

bluebird bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The business had revenue of $7.71 million for the quarter, compared to the consensus estimate of $8.47 million. During the same period in the prior year, the business posted ($2.07) earnings per share. The firm’s revenue for the quarter was up 397.4% compared to the same quarter last year. equities analysts predict that bluebird bio, Inc. will post -6.72 EPS for the current fiscal year.

BLUE has been the topic of a number of research analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $174.00 target price (up from $135.00) on shares of bluebird bio in a report on Thursday, November 2nd. Cantor Fitzgerald reaffirmed a “sell” rating and issued a $39.00 target price on shares of bluebird bio in a report on Thursday, September 28th. Evercore ISI raised shares of bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 target price on the stock in a report on Monday, October 16th. BMO Capital Markets upped their target price on shares of bluebird bio from $134.00 to $162.00 and gave the company a “buy” rating in a report on Monday, October 30th. Finally, Goldman Sachs Group reaffirmed a “buy” rating and issued a $186.00 target price on shares of bluebird bio in a report on Friday, October 6th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and thirteen have given a buy rating to the stock. bluebird bio currently has an average rating of “Hold” and an average target price of $157.45.

In related news, insider David Davidson sold 4,000 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $131.31, for a total transaction of $525,240.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Jeffrey T. Walsh sold 4,900 shares of the stock in a transaction that occurred on Tuesday, October 10th. The stock was sold at an average price of $129.94, for a total transaction of $636,706.00. The disclosure for this sale can be found here. Insiders have sold 215,082 shares of company stock worth $37,227,332 over the last ninety days. Insiders own 3.90% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://www.com-unik.info/2017/12/27/bluebird-bio-inc-blue-shares-bought-by-legal-general-group-plc.html.

bluebird bio Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

What are top analysts saying about bluebird bio? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for bluebird bio and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit